Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 10;13(7):1120.
doi: 10.3390/jpm13071120.

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Dirk Rades  1 , Inga Zwaan  1 , Christian Idel  2 , Ralph Pries  2 , Karl L Bruchhage  2 , Samer G Hakim  3   4 , Nathan Y Yu  5 , Tamer Soror  1
Affiliations

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Dirk Rades et al. J Pers Med. .

Abstract

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients' scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90-100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned.

Keywords: chemoradiation; cisplatin; completion of treatment; head and neck cancer; prognostic instrument.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Adelstein D.J., Lavertu P., Saxton J.P., Secic M., Wood B.G., Wanamaker J.R., Eliachar I., Strome M., Larto M.A. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88:876–883. doi: 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y. - DOI - PubMed
    1. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.L., Greiner R.H., Giralt J., Maingon P., Rolland F., Bolla M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004;350:1945–1952. doi: 10.1056/NEJMoa032641. - DOI - PubMed
    1. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004;350:1937–1944. doi: 10.1056/NEJMoa032646. - DOI - PubMed
    1. Zwaan I., Soror T., Bruchhage K.L., Hakim S.G., Schild S.E., Rades D. Comparison of two cisplatin regimens for chemoradiation in patients with squamous-cell carcinoma of the head and neck. Anticancer Res. 2023;43:795–800. doi: 10.21873/anticanres.16220. - DOI - PubMed
    1. De Castro G., Jr., Snitcovsky I.M., Gebrim E.M., Leitão G.M., Nadalin W., Ferraz A.R., Federico M.H. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2007;264:1475–1482. doi: 10.1007/s00405-007-0395-9. - DOI - PubMed

LinkOut - more resources